semaglutide and alcohol use disorder People with obesity had fewer heavy drinking days while on (Wegovy), a Danish randomized trial showed. Semaglutide-treated adults also showed greater improvements across multiple secondary alcohol-related and GLP-1 medications: The next big

The initiative reflects a shared healthcare strategy to bridge the pharmaceutical and technology sectors and help advance a digital health ecosystem that empowers patients to build healthy daily habits aligned with clinical guidance for FDA-approved medicines

There is no simple yes or no

Backed by powerful antioxidants, it not only lightens the skin but also nourishes it from within, offering long-term beauty and protection

Trial registration Clinicaltrialsregister.eu EudraCT 2019-000781-38 Funding Novo Nordisk Foundation, Central Denmark Region Research Fund and Danish Medical Associations Research Foundation Graphical abstract Similar content being viewed by others Introduction Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease (CKD) in the USA and other western societies [1]